EyePoint Pharmaceuticals, Inc. (EYPT)の価格はいくらですか

EyePoint Pharmaceuticals, Inc. (EYPT)の価格は$4.48です

EyePoint Pharmaceuticals, Inc. (EYPT)の時価総額は何ですか

EyePoint Pharmaceuticals, Inc. (EYPT)の時価総額は$375.37Mです

EyePoint Pharmaceuticals, Inc.（EYPT）営業利益率

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.

年	営業利益率	変化
提供された日付のデータは十分ではありません。

年

営業利益率

変化

提供された日付のデータは十分ではありません。

企業	営業利益率	営業利益率の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.57%	-	AU
Moderna, Inc. MRNA.US	-149.01%	-	US
Lonza Group AG LONN.SW	0.00%	-	CH

企業

営業利益率

営業利益率の差

国